Last updated October 21, 2026. Approval line checked October 21, 2026. Compounding sources checked October 10, 2026.
FDA status
Not approved
Not approved. This record is not an FDA-approved drug product. Approval, where it exists, is specific to a drug product, indication, and route.
FDA primary source on fileBy signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Evidence tier
Human RCT. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 3/5. 380 PubMed citations indexed.
Products sold as "research use only" are not approved for human use. FDA warning.
Second-generation GHRP ghrelin mimetic strongly stimulating GH release via GHSR-1a; increases appetite and has mild anti-inflammatory activity.
What the literature studies
Growth Hormone Stimulation
Evidence tier
Human RCT
Compounding record
503B Category 2 / 503A Category 3
503B Category 2 / 503A Category 3. FDA substance context: GHRP-2 for injectable and nasal routes. 503B Category 2 identifies potential significant safety risks; 503A Category 3 means the nomination lacks adequate supporting information. Neither classification establishes approval or compounding eligibility. Other routes are not verified. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.
Regulatory source checked October 10, 2026. This compounding label is separate from the approval line above.
associated with serious adverse events in critically ill patients including death and pancreatitis.
By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.